Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Peptide Schedule Research TeamReviewed Oct 13, 202611 Citations
Orforglipron Dosage Calculator
Weight Loss · FDA Approved · Grade B · ~29-49 hours half-life · Oral
Orforglipron Dosage
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 0.8 mg | Daily |
| Moderate | 5.5 mg | Daily |
| Aggressive | 17.2 mg | Daily |
Cycle: No scheduled off period.
No syringe calculation for this route
Oral
Orforglipron has no default water volume for this calculator, so there are no syringe units to calculate here. Dosing runs 0.8 mg to 17.2 mg per administration, daily.
If your product does arrive as a powder, use the universal reconstitution calculator and enter your own vial size and water volume.
About Orforglipron
Beginner, moderate, and aggressive dosing amounts with timing. Free to use.
Orforglipron (Foundayo) is the first oral non-peptide GLP-1 receptor agonist, FDA-approved April 2026. No injections, no fasting restrictions. The ATTAIN-1 trial showed 11.2% average weight loss at 72 weeks, though GI side effects ran higher than on oral semaglutide in a head-to-head trial.
View side effects and safety warnings →
Quick-Start: How to Use Orforglipron
- 1Pick a consistent time of day that works for your schedule. Morning, evening, or midday all work fine.
- 2Take one tablet by mouth. Swallow it whole with whatever amount of water you prefer. No crushing, breaking, or chewing.
- 3Food doesn't matter. You can take it on an empty stomach, with a meal, or with a snack. No restrictions.
Orforglipron Dosing Protocol
| Level | Dose | Frequency |
|---|---|---|
| Beginner | 0.8 mg | Daily |
| Moderate | 5.5 mg | Daily |
| Aggressive | 17.2 mg | Daily |
Oral tablet. No vials, no syringes, no reconstitution math. That alone makes orforglipron the simplest GLP-1 drug to start.
Titration schedule matters more than most beginners realize. You start at 0.8 mg daily for a full 30 days before moving to 2.5 mg. Then 5.5 mg for another 30 days. After that, you can escalate to 9 mg, 14.5 mg, or 17.2 mg based on how your body responds. Skipping steps or rushing the schedule significantly increases nausea and GI side effects.
The detail that catches people off guard: if you miss 7 or more consecutive doses, you restart the entire titration from 0.8 mg. Not from where you left off.
Swallow the tablet whole. Don't crush, break, or chew it. Take it any time of day, food or no food, water or no water. No awkward 30-minute fasting window like Rybelsus.
Constipation hits harder than most expect (20 to 27% across doses in the label's weight trials, vs 9% on placebo). Start extra fiber and fluids on day 1, not after symptoms appear. Each dose escalation step tends to bring a fresh wave of nausea for 5 to 7 days; plan increases during low-stress weeks.
Dosing based on Foundayo (orforglipron) FDA Prescribing Information (2026): 11 published references.View all sources →
Ask AI about this math
Cross-check your Orforglipron reconstitution math with AI
Orforglipron Cost
Pricing updated 2026-04-09
Prices are estimates and vary by source, location, and prescription status.Full pricing breakdown →
Orforglipron Pharmacokinetics
Pharmacokinetics: Active Dose Over Time
t½ = ~29-49 hoursDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Related Tools
Frequently Asked Questions
How popular is Orforglipron?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
79 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.